Evidence Paper Review

 Quick Explanation Copied

 Long Explanation

Core Mechanistic Model: Opposing SCFA Receptors Buffer Blood Pressure

The addendum distills the parent PNAS study into a parsimonious two-receptor model: gut microbiota–derived propionate (<0.1–10 mM plasma) activates the low-affinity receptor Olfr78 (EC50 propionate 920 µM) to raise BP via renin release from afferent arteriole JG cells, while simultaneously activating the higher-affinity receptor Gpr41 (EC50 propionate 274 µM) to lower BP via vasodilation Quantitative BP responses to propionate in KO models. The EC50 differential elegantly explains the 'brake' logic: Gpr41 is active at basal propionate, Olfr78 only at higher concentrations, preventing dangerous hypotensive dips.

Affinity ordering (Gpr43 ≈ Gpr41 << Olfr78) is the paper's strongest quantitative argument for its functional model Comparative EC50 table across SCFA receptors.

Evidence Strengths and Critical Gaps

Strengths: convergent methods (β-gal reporter localization, luciferase ligand screen, quinacrine renin-granule release, IV propionate telemetry, antibiotics + 16S rRNA), human ortholog (OR51E2) confirmation, and a falsifiable antibiotic experiment — BP rose in Olfr78−/− but not +/+ mice when microbiota were depleted, exactly as the buffering model predicts Antibiotic experiment supporting buffering model.

Critical gaps: (1) Gpr41/Gpr43 were localized to vessels only by RT-PCR on intact vessels — endothelial vs. smooth muscle cell identity remains unknown, leaving the downstream signaling mechanism (Gi/cAMP vs. NO) unresolved; (2) the basal hypotension in Olfr78−/− cannot be attributed to vascular tone vs. chronically low renin; (3) all data are mouse; human plasma propionate (1.4–13.4 µM in later reviews) is far below Olfr78's 920 µM EC50, challenging direct translation Dalile review on SCFA systemic concentrations; (4) 'postprandial hypotension facilitates absorption' is speculative teleology, not tested; (5) no confounder control for antibiotic effects independent of microbiota (e.g., direct vascular effects). The authors candidly flag several of these, which is a credibility positive.

Historical Significance

This work seeded the now-large microbiome–cardiovascular field: Olfr78/OR51E2 is now routinely listed among canonical SCFA receptors alongside FFAR2/FFAR3 in gut–brain and renal physiology reviews OR51E2 now canonical SCFA receptor. Confidence: mechanistic claims well-supported in mice (strong); human BP relevance remains inferred (moderate).

 BGPT Paper Review

Study Novelty

First identification of an olfactory receptor as a SCFA sensor regulating BP via microbiota — a genuinely unexpected receptor class in vascular/renal physiology, later validated as canonical.

Scientific Quality

Rigorous multi-method mouse work with human ortholog confirmation and a falsifiable antibiotic test; but purely preclinical, localization of Gpr41/43 incomplete, and basal-BP causality (renin vs. tone) unresolved.

Study Generality

Establishes a broad principle — microbiota metabolites as endocrine BP signals via ectopically expressed sensory receptors — though specifics are murine and receptor-specific.

Study Usefulness

Opened microbiome–hypertension therapeutic avenue (diet, probiotics, OR51E2 drugs); directly shaped subsequent renal, gut–brain, and cardiovascular SCFA research.

Study Reproducibility

Methods (luciferase assay, reporter mice, KO lines, quinacrine assay) are standard and described; no raw data deposit, and some figures rely on parent-paper methods.

Explanatory Depth

EC50-based quantitative logic linking receptor affinity to physiological buffering is genuinely mechanistic; but downstream signaling (Gi vs Gs vs NO) remains hypothesis-level.